2256.HK

Abbisko Cayman Limited 2256.HK

2256.HK
Abbisko Cayman Limited 2142.HK
HBM Holdings Limited 2171.HK
CARsgen Therapeutics Holdings Limited 2616.HK
CStone Pharmaceuticals 2315.HK
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. 6826.HK
Shanghai Haohai Biological Technology Co., Ltd. 9966.HK
Alphamab Oncology 6699.HK
Angelalign Technology Inc. 2157.HK
Lepu Biopharma Co., Ltd. 1672.HK
Ascletis Pharma Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode 2256.HK 2142.HK 2171.HK 2616.HK 2315.HK 6826.HK 9966.HK 6699.HK 2157.HK 1672.HK
6M 129.97 % 79.94 % 38.15 % 166.93 % 105.08 % 12.37 % 112.67 % 28.95 % 65.40 % 90.28 %
YTD 256.69 % 552.53 % 87.63 % 173.47 % 191.57 % 5.78 % 311.08 % 4.14 % 159.92 % 190.12 %
1Y 305.41 % 917.32 % 338.90 % 272.22 % 223.10 % -19.52 % 267.19 % -2.11 % 110.61 % 596.30 %
3Y 438.70 % 843.07 % 31.93 % 78.19 % -10.37 % 60.62 % 136.97 % -26.40 % -15.16 % 293.31 %
5Y 26.85 % 17.24 % -41.33 % -45.08 % -6.92 % -16.03 % -8.32 % -84.95 % -8.26 % 214.38 %
10Y 26.85 % 17.24 % -41.33 % -47.90 % -6.92 % -15.38 % 4.44 % -84.95 % -8.26 % -32.86 %
From the beginning 26.85 % 17.24 % -41.33 % -47.90 % -6.92 % -35.08 % 4.44 % -84.95 % -8.26 % -32.86 %

Dividend

Shanghai Haohai Biological Technology Co., Ltd.

Angelalign Technology Inc.